Balance sheet as at December 31
in CHF | Notes | 2024 | 2023 | |||
Current assets | ||||||
Cash and cash equivalents | 125 695 | 44 757 | ||||
Other current receivables | 5 022 840 | 5 992 571 | ||||
5 148 535 | 6 037 328 | |||||
Non-current assets | ||||||
Investments | 1 177 069 500 | 1 177 069 500 | ||||
1 177 069 500 | 1 177 069 500 | |||||
Total assets | 1 182 218 035 | 1 183 106 828 | ||||
Current liabilities | ||||||
Other current liabilities | 348 387 | 334 219 | ||||
Accrued expenses | 801 979 | 467 774 | ||||
1 150 366 | 801 993 | |||||
Total liabilities | 1 150 366 | 801 993 | ||||
Shareholders' equity | ||||||
Share capital | 11 080 000 | 11 080 000 | ||||
Legal capital reserves | ||||||
- Paid-in capital reserve 1) | 20 579 224 | 20 579 224 | ||||
Legal profit reserves | ||||||
- General legal reserve | 4 500 000 | 4 500 000 | ||||
- Reserve for treasury shares 2) | 39 640 314 | 36 508 182 | ||||
Other reserves | 187 187 442 | 190 319 574 | ||||
Retained earnings | 921 212 821 | 919 317 855 | ||||
Treasury shares | (3 132 132) | – | ||||
1 181 067 669 | 1 182 304 835 | |||||
Total liabilities and shareholders' equity | 1 182 218 035 | 1 183 106 828 |
1Of which CHF 20 441 000 not confirmed by the Swiss Tax Authorities due to present regulation
2For treasury shares held by BB Biotech AG and subsidiaries
The financial statements were approved by the Board of Directors of BB Biotech AG on February 18, 2025.